EGFR and non-small cell lung carcinoma: In summary, to our knowledge, our study is a retrospective clinical study describing the clinical characteristics and EGFR-TKI treatment outcomes of NSCLC patients with EGFR common double mutations, including 19Del, L858R, and T790M.